Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI305 + pemetrexed ± cisplatin in EGFR-mutant nonsquamous NSCLC after TKI failure
CTR20182559Phase 3Suspended
- Sponsor
- Innovent Biologics
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Innovent Biologics. Started Jan 2019; status: suspended.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20182559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182559.